Sanat.io logo
71
Публикувано отYana Nencheva
преди 1 година
1 Коментара

Вижте още теми в
  • 1
    Boyan Dimitrov
    преди 1 година

    Бе май не е така. Извадките им са силно ограничени. Ремдисивир-ът май е единственото, което наистина е потвърдено, че действа или поне аз бих заложил на него, ако имам въобще правото на избор в случай на нужда.

    Обобщение по въпроса:

    The three most promising treatments currently being investigated are two antivirals, Remdesivir and Favipiravir, and an antimalarial drug called chloroquine (and its close relative, hydrochloroquine).

    Remdesivir is an antiviral drug owned by Gilead Sciences Inc. (NASDAQ: GILD), a pharma company out of California. The drug has been tested against Ebola, where it failed, but also against SARS and MERS, two viruses closely related to the one currently sweeping the globe. In lab tests, it works against both, and the World Health Organization's team lead in China, Bruce Awylward, considers Remdesivir the "only drug right now that we think may have real efficacy."

    It has already been used in Washington and California for severe cases of COVID-19, under a compassionate exemption from having to be FDA approved. The volume of those requests is so high that Gilead had to develop a special system just for Remdesivir, as requests for compassionate use of other drugs were being swamped.

    The WHO has just launched a large, global trial of several promising treatments for coronavirus, and Remdesivir is one of them.

    Favipiravir is a Japanese antiviral drug, made by a subsidiary of Fujifilm, which is targeted mainly against the flu.

    In a Chinese study on 340 coronavirus patients, people given Favipiravir tested virus-free after a median of about four days, compared to 11 days in subjects that did not receive the drug. That's more than a 50% reduction, which would translate to much higher hospital capacity.

    Ninety-one percent of patients given the drug also showed cleared lungs on CT scans, compared to only 62% without it.

    However, this study is fairly small, and a larger one is needed to get more definitive results. Japanese officials have said that in their experience, Favipiravir does not work in patients where the infection has progressed too far. The drug may end up being added to the WHO's global trial.

    Finally, we have chloroquine and hydrochloroquine. These are mainly antimalarial drugs, first developed in 1934. They are also used against some parasites, as well as against some autoimmune diseases.

    While the drugs seem to act against a variety of viruses in lab cultures, including chikungunya and dengue, tests in people showed no effect. Lab cultures show only extremely high doses working against the coronavirus, but several studies in China claim to show that the drugs work well against the coronavirus at smaller doses.

    However, the underlying data for those studies has not been made public, nor been shared with the WHO. This makes chloroquine a bit of a long shot, even though the drug has received much attention online and from U.S. President Donald Trump.

    And these are only the top candidates. With so much drug testing going on, including a $125 million grant from the Bill & Melinda Gates Foundation, a treatment is bound to be discovered, even if it's not any of the drugs mentioned above.